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Plumbagin is a natural compound that is isolated from the root of the medicinal plant Plumbago zeylanica
L. Based on a previous in vitro study performed by our group, which demonstrated the effectiveness of
plumbagin against glioma cells, we further ascertained whether plumbagin exhibits the same effec-
tiveness against glioma cell xenografts in nude mice. Our results revealed that tumor volume was
reduced by 54.48% in the plumbagin-treated group compared with the controls. Furthermore, there were
no obvious signs of toxicity as assessed by the organ sizes and cell morphologies of the mice that were
treated with plumbagin. Immunoﬂuorescence assays further revealed that plumbagin signiﬁcantly
inhibited glioma cell proliferation and induced cell apoptosis. Importantly, we also determined that the
expressions of FOXM1 and its downstream target effectors, including cyclin D1 and Cdc25B, were down-
regulated in the treated group, while the expressions of p21 and p27 were increased; the latter ﬁndings
corroborate the results of our previous in vitro study. Taken together, these ﬁndings indicate that
plumbagin may be a natural downregulator of FOXM1 with potential therapeutic effectiveness for the
treatment of gliomas.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Glioblastoma multiforme (GBM) is the most common primary
brain tumor and is also the most deadly glioma (1). Currently, the
standard treatment for malignant glioma is surgery followed by
external radiation and chemotherapy. However, these treatments
are not efﬁcacious; the median survival is still 15e18 months from
diagnosis (2). Temozolomide (TMZ) is an alkylating agent that is
often used in the management of GBM patients in combination
with radiotherapy. However, the efﬁcacy of TMZ is limited due to
the occurrence of chemoresistance and the inability of TMZ to), yu.rutong@163.com (R. Yu).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).induce tumor cell death (3e5). Therefore, the development of more
effective therapeutic agents is critical for the treatment of high-
grade gliomas in neurooncology.
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is an
active constituent of the roots of the medicinal plant Plumbago
zeylanica L that has been demonstrated to exhibit antimicrobial (6),
antiatherosclerotic (7), and anticarcinogenic effects (8). A large
number of published studies have suggested that plumbagin ex-
hibits anti-proliferative and pro-apoptotic properties in a variety of
tumor cell lines and animal tumor models (9e12). Plumbagin has
been reported to induce the generation of reactive oxygen species
(ROS), which results in apoptosis and cell cycle arrest (13, 14). Some
studies have also shown that plumbagin inhibits the Akt/mTOR and
NF-kB pathways in breast cancer (15, 16). Additionally, plumbagin
has been reported to inhibit tumor angiogenesis and tumor growth
in endothelial cells (17). Furthermore, some in vivo studies of the
effects of plumbagin on tumorigenesis have revealed that plum-
bagin can signiﬁcantly inhibit tumor cell growth in various animalnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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cancer (18), breast cancer (15) and leukemia (19). A previous in vitro
study performed by our group demonstrated that plumbagin in-
hibits glioma cell growth and induces apoptosis (20). However, the
efﬁcacy of plumbagin in the treatment of gliomas in vivo has yet to
be investigated.
Forkhead box M1 (FOXM1) is a transcription factor that induces
the expression of genes involved in cell cycle progression and
apoptosis (21, 22). Because the proliferation-specific oncogenic
gene FOXM1 is strongly up-regulated in a variety of human tumors,
including GBMs, it is considered an attractive target for the pre-
vention of and/or therapeutic interventions for cancer (23e26).
However, little information regarding FOXM1 inhibitors is currently
available. Recent research has demonstrated that FOXM1 knock-
down sensitizes recurrent GBM cells to TMZ cytotoxicity (27). In our
previous study, we found that plumbagin exerts its anti-tumor
activities partially by inhibiting FOXM1 activity in gliomas (20).
However, in vivo studies are also needed to further ascertain anti-
tumor activity of plumbagin via the inactivation of FOXM1.
In this study, we report that plumbagin inhibited glioma cell
proliferation and promoted apoptosis in a nude mouse model. We
also observed that the plumbagin-mediated inhibition of the cell
growth was accompanied by inhibitions of the expressions of
FOXM1, downstream target genes of FOXM1 (i.e., cyclin D1 and
Cdc25B), and proliferative markers (Ki67) and induction of the
expressions of p21, p27 and cleaved caspase-3.
2. Materials and methods
2.1. Cell lines and culture conditions
All of the human glioma cell lines used in this study (i.e., U87,
A172, SHG44, and U251) were purchased from the Shanghai Cell
Bank of the Chinese Academy of Sciences (CAS). These cells were
cultured in DMEM/F-12 media supplemented with 10% fetal bovine
serum (FBS, Sijiqing Bioengineering Material Co., China) and grown
in a humidiﬁed incubator with 5% CO2 at 37 C.
2.2. Antibodies and reagents
Antibodies against cleaved caspase-3, cyclin D1, Cdc25B, p21,
p27, and b-actin were obtained from Cell Signaling Technology. The
anti-FOXM1 antibody was acquired from Santa Cruz, and Ki67 was
from Thermo. Leibovitz's L-15 was purchased from Gibco. Plum-
bagin and all other chemicals were purchased from SigmaeAldrich.
2.3. Cell viability assay
Cell viability was measured with the CCK-8 assay. In brief, gli-
oma cells were seeded in 96-well plates and incubated overnight.
Then, the cells were treated with plumbagin at different concen-
trations (0.625, 1.25, 2.5, 5, 10 and 20 mM) for 48 h. CCK-8 reagent
(10 mL) was added to the cells, and the plates were then read at
450 nm using a spectrophotometer.
2.4. Glioma xenografts in nude mice
The study was approved by the Ethics Committee of the Xuzhou
Medical College. Female athymic nude mice aged 4e6 weeks were
purchased from the Experimental Animal Center of Xuzhou Medi-
cal College and maintained in pathogen-free conditions. U87 cells
(1  106 cells) in 100 mL of Leibovitz's L-15 were transplanted
subcutaneously into the right ﬂanks of the mice. When the tumors
reached 100e150mm3, treatment was initiated. The tumor-bearing
mice were randomly divided into two groups (n ¼ 5 per group).Group 1 was treated with vehicle (0.9% sodium chloride) alone, and
Group 2 was treated with plumbagin in vehicle at a dose of 2 mg/
kg/day via intraperitoneal injections that were performed 5 times
per week. All of the mice were sacrificed after 24 days of treatment.
The tumors and vital organs of the control and treated mice were
harvested and prepared for histological study.2.5. Histopathology
The tumors and liver, kidney and lung tissues were ﬁxed in 4%
paraformaldehyde and then dehydrated in 20% followed by 30%
sucrose at 4 C until they sank. The fresh-frozen tissues were
continuously sectioned at a thickness of 12 mm and then stained
with hematoxylineeosin (HeE) for microscopic examination. The
tumor sizes were measured using calipers, and the tumor volumes
were calculated according to the following formula: V
(mm3) ¼ a  b2/2, where a is the longest tumor axis, and b is the
shortest tumor axis.2.6. Immunoﬂuorescence staining
The sections containing the tumor were incubated with 0.3%
triton X-100 followed by 10% goat serum and were then incubated
overnight with Ki67 or cleaved caspase-3 primary antibody at 4 C.
To visualize the Ki67- or cleaved caspase-3-positive cells, the sec-
tions were incubated with Alexa-594-conjugated secondary anti-
body for 1 h at room temperature in the dark. DAPI was used to
stain the cell nuclei. All sections were examined and photographed
with a microscope with an attached ﬂuorescence detector (IX71
Olympus).2.7. Western blot analysis
Parts of the excised tumor tissues of the gliomas from each
group of mice were used to prepare whole tissue lysates. Total
protein extracts from the tumor tissue lysates were subjected to
Western blot analyses as described previously (28). The expressions
of FOXM1, p21, p27, cyclin D1 and Cdc25B were examined with
speciﬁc primary antibodies, and b-actin was used as the loading
control.2.8. Statistical analysis
The data are presented as the means and the standard de-
viations of three to ﬁve independent experiments. Signiﬁcant dif-
ferences between the control and plumbagin-treated groups were
determined with Student's t tests. Values of P < 0.05 were
considered statistically significant.3. Results
3.1. Plumbagin inhibits glioma cell growth in vitro
To assess the efficacy of plumbagin against glioma cells in vitro,
we ﬁrst examined the effects of plumbagin on glioma cell viability
using the CCK-8 assay. As shown in Fig. 1, all of the glioma cells from
all four of the glioma cell lines that were treated with plumbagin
exhibited inhibitions in growth that were concentration- and time-
dependent. The IC50 values of plumbagin for the inhibition of the
glioma cell lines are summarized in Fig. 1D. The greatest activity
was observed against the U87 cells, and the IC50 value obtained for
this cell line was 2.83 mM at 72 h of incubation. These data indicate
that plumbagin signiﬁcantly inhibited glioma cell growth in vitro.
Fig. 1. Effect of plumbagin on the viability of glioma cells in vitro. Cells were treated with vehicle (0.1% DMSO) or different concentrations of plumbagin (0.625, 1.25, 2.5, 5, 10 and
20 mM) for 24 (A), 48 (B) and 72 h (C). Cell viability was measured with CCK-8 assays. (D) The IC50 values of for the SHG-44, U251, U87 and A172 cell lines at 24, 48 and 72 h.
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A large number of studies of other tumors types have shown
that plumbagin inhibits tumorgenesis in mouse tumor models (15,
18, 29). After demonstrating the effects of plumbagin on glioma cell
growth in vitro, we tested the ability of plumbagin to inhibit glioma
growth in vivo. We injected U87 cells subcutaneously into right
ﬂanks of nude mice. The treatments were continued for 24 days for
the mice that were injected with U87 tumor cells. All of the control
mice were treated with an equal volume of 0.9% sodium chloride.
As shown in Fig. 2A and B, the inhibition of tumor growth wasmost
evident in themice that were treatedwith plumbagin at 2mg/kg/d;
an approximately 54.48% reduction in tumor size was observed in
this group. The average tumor volumes were 2393.72 mm3 in the
control group and 1029.73 mm3 in the plumbagin-treated group.
We also observed an obvious difference in tumor weight between
the treated and control groups. Compared with the control group,
the tumor weight was reduced by 44.54% in the plumbagin-treated
group (Fig. 2D). These results suggest that plumbagin inhibited
glioma cell growth in vivo.
Next, we examined the toxicity of plumbagin in vivo via parallel
monitoring of the bodyweights and examinations of theH&E stained
tissue sections of the livers, kidneys and lungs of the plumbagin-
treated mice. As shown in Fig. 2C, gross examinations of the vital
organs, i.e., the lungs, livers and kidneys, of the plumbagin-treated
and control groups revealed similar sizes and cell morphologies.
3.3. Effects of plumbagin on cell proliferation and apoptosis in vivo
To further study the effects of plumbagin on tumor growth
in vivo, Ki67 and cleaved caspase-3 were used to evaluate cell
proliferation and apoptosis, respectively. The percentage of Ki67-
positive cells was decreased by 51.65% in the plumbagin-treated
group (Fig. 3A and B). In contrast, the percentage of apoptotic
cells was signiﬁcantly increased by 51.28% in the plumbagin-
treated group (Fig. 3C and D). Taken together, these data reveal
that plumbagin can inhibit tumor cell proliferation and induce cell
apoptosis in vivo.3.4. Effects of plumbagin on the expressions of FOXM1 and its
downstream target genes in vivo
A previous in vitro study performed by group demonstrated that
plumbagin inhibits glioma cell growth by down-regulating the
expression of FOXM1 (20). To further ascertain whether plumbagin
exerts the same effect on FOXM1 expression in vivo, we extracted
the total proteins from the tumor tissues to assess the levels of
FOXM1 and its downstream effectors in the control and plumbagin-
treated groups. As shown in Fig. 4, the FOXM1, cyclin D1 and
Cdc25B levels were decreased in the tumors from the plumbagin-
treated group compared with the tumors from the control group.
In contrast, the p21 and p27 levels were increased in the
plumbagin-treated group. Together with the data from our previ-
ous study, these data demonstrate that plumbagin-mediated anti-
tumor activity occurs via the inactivation of FOXM1.
4. Discussion
Malignant glioma has long resulted in high mortality rates
worldwide. Unfortunately, there is no effective therapy for this
malignant disease due to its rapid proliferation, high invasiveness
and resistance to radiotherapy and chemotherapy (30, 31). There-
fore, it is necessary to develop highly effective and safe drugs for
the treatment of gliomas. The previous study performed by our
group demonstrated that plumbagin effectively inhibits glioma cell
growth, migration and invasion in vitro (20). In the present study,
we generated gliomas in nude mice via the implantation of U87
cells to further evaluate the effect of plumbagin in vivo. Our results
indicated that plumbagin signiﬁcantly inhibited gliomagenesis and
tumor growth in this nude mice model. Additionally, we also found
that the plumbagin-mediated antitumor activity was accompanied
by the inhibition of the expression of FOXM1 in vivo, which cor-
roborates the results of our previous in vitro study (20).
A number of studies have demonstrated the potential usefulness
of plumbagin as an anti-cancer treatment (14, 29, 32). Plumbagin
has been demonstrated to signiﬁcantly inhibit tumorigenesis and
tumor cell growth in vivo in breast cancer (11, 15), lung cancer (29),
Fig. 2. Plumbagin inhibits glioma cell growth in vivo. (A) Representative tumor-bearing nude mice and tumors isolated from the control and plumbagin-treated groups. (B) The
mean tumor volumes were assessed at the indicated numbers of days after plumbagin treatment. (C) Tissue sections of the livers, kidneys and lungs stained with H&E from the
control and plumbagin-treated mice were observed; scale bar ¼ 100 mm. (D) The mean tumor weights were measured. The data obtained from three independent experiments are
represented as the means ± the SEMs. *P < 0.05, plumbagin vs. vehicle-treated mice.
M. Niu et al. / Journal of Pharmacological Sciences 128 (2015) 131e136134and prostate cancer (18). Consistently, we found that treatment
with plumbagin resulted in significant glioma growth inhibition in
mice compared to the untreated group. No signs of toxicity were
observed in the plumbagin-treated group as assessed with H&E
staining of the vital organs, which is consistent with previous
studies that have observed no toxic inﬂuences of plumbagin on
vital organs, including the liver, kidneys and lungs, when used
against breast cancer (15) and leukemia (19). The Ki67 and cleaved
caspase-3 proteins are cellular markers of proliferation and
apoptosis, respectively (33, 34). The signiﬁcant reduction in Ki67-
positive cells and signiﬁcant increase in cleaved caspase-3
expression further indicate that plumbagin effectively inhibited
gliomagenesis and glioma cell growth in vivo, and these results
corroborate those of our previous in vitro study (20).
FOXM1 is an oncogenic transcription factor that is overex-
pressed in various human malignancies, including GBM, and is
closely associated with tumor cell proliferation and apoptosis (26,
35). In addition to our previous investigation, many other studies
have found that the down-regulation of FOXM1 inhibits glioma cell
growth (26, 36, 37). Thus, the development of agents targeting
FOXM1 could have signiﬁcant therapeutic implications for the
treatment of gliomas (38). We have previously reported thatplumbagin inhibits glioma cell growth by down-regulating the
expression and activity of FOXM1 in vitro (20). Consistently, we also
found that FOXM1 was down-regulated in plumbagin-treated mice
compared with control mice. Furthermore, the expressions of
downstream target effectors of FOXM1 were also affected by
plumbagin treatment. These results further support the conclusion
that the down-regulation of FOXM1 mediates the plumbagin-
induced inhibition of glioma cell growth in vivo. However, in-
depth studies of the mechanism by which plumbagin regulates
FOXM1 should be performed in the future.
In conclusion, our present findings support those of our previ-
ous in vitro study and suggest that plumbagin inhibits glioma-
genesis and tumor cell growth via the inactivation of FOXM1.
Moreover, we strongly believe that plumbagin may function as a
potential downregulator of FOXM1 and could be useful in the
treatment of malignant gliomas.
Ethical statement
All procedures performed in the studies involving animals were
in accordance with the ethical standards of the Xuzhou Medical
College.
Fig. 3. The effects of plumbagin on cell proliferation and apoptosis in vivo. Tumor cell proliferation and apoptosis were assessed with anti-Ki67 (A) and anti-cleaved caspase-3
immunostaining (C). (B) and (D) Quantitative analyses of the percentages of positive cells in the plumbagin-treated group normalized to the control group. These results are
presented as the means ± the SEMs of three independent experiments. *P < 0.05, scale bar ¼ 50 mm.
Fig. 4. The effects of plumbagin on the expression of FOXM1 and its downstream effectors in vivo. (A) Plumbagin inhibits the expression of FOXM1 in U87 xenografts. (B) Mod-
ulation of the protein expressions of the downstream target genes of FOXM1 by plumbagin in U87 xenografts.
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